NCT05463354View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

PHASE2CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

August 18, 2022

Study Completion Date

January 26, 2024

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Recombinant COVID-19 Vaccine (Sf9 Cell)

1dose, Intramuscular Injection

BIOLOGICAL

COVID-19 Vaccine (Vero Cell), Inactivated

1dose, Intramuscular Injection

Trial Locations (1)

Unknown

Iloilo Doctors Hospital, Iloilo City

All Listed Sponsors
lead

WestVac Biopharma Co., Ltd.

INDUSTRY